PROK PROKIDNEY CORP.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1850270 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY4.2%
TTM net income YoY-45.4%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-24,830.3%
Net margin-13,326.7%
FCF margin-21,655.0%
EBITDA margin-24,002.1%
Returns
ROE—
ROA-36.8%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets15.8%
Debt / equity—
Current ratio5.04x
Interest coverage-10,690.83x
Cash quality & payout
Operating cash flow / net income1.48x
Accruals ratio17.8%
Payout ratio—
Capex / revenue1,884.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $174,000 | $150,000 | $226,000 | $225,000 | $217,000 | $221,000 | $230,000 | $76,000 |
| R&D expense | $40.84M | $36.09M | $33.84M | $34.16M | $26.82M | $25.88M | $27.26M | $39.78M |
| SG&A expense | $13.09M | $12.43M | $11.32M | $11.44M | $11.94M | $14.05M | $14.36M | $11.87M |
| Operating income | -$53.76M | -$48.37M | -$44.93M | -$45.37M | -$38.54M | -$39.71M | -$41.39M | -$51.57M |
| Interest expense | $1,000 | $1,000 | $15,000 | $1,000 | $2,000 | $1,000 | $0 | $2,000 |
| Pretax income | -$52.23M | -$46.44M | -$42.62M | -$42.44M | -$35.28M | -$36.12M | -$37.36M | -$46.78M |
| Income tax | -$436,000 | $0 | $0 | -$1.58M | $560,000 | $848,000 | $591,000 | $1.70M |
| Net income | -$35.59M | -$28.42M | -$20.04M | -$19.23M | -$16.47M | -$16.55M | -$16.73M | -$21.28M |
| EBITDA | -$52.28M | -$46.92M | -$43.27M | -$43.53M | -$37.14M | -$38.22M | -$39.79M | -$50.00M |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $81.36M | $74.87M | $101.89M | $108.54M | $95.32M | $84.94M | $97.81M | $99.12M |
| Current assets | $151.45M | $189.77M | $234.90M | $280.68M | $299.99M | $324.44M | $359.66M | $395.88M |
| PP&E, net | $55.81M | $56.04M | $54.44M | $51.23M | $47.75M | $43.52M | $43.33M | $42.22M |
| Total assets | $210.28M | $249.02M | $292.78M | $335.57M | $351.61M | $372.13M | $406.06M | $441.07M |
| Current liabilities | $30.04M | $22.71M | $25.93M | $30.74M | $29.06M | $28.26M | $32.81M | $36.22M |
| Total liabilities | $33.30M | $26.18M | $29.68M | $34.78M | $33.27M | $32.68M | $36.08M | $39.44M |
| Shareholders' equity | -$906.85M | -$883.53M | -$1.02B | -$1.01B | -$1.01B | -$1.00B | -$998.55M | -$994.95M |
| Cash flow statement | ||||||||
| Operating cash flow | -$38.65M | -$40.37M | -$41.68M | -$32.51M | -$26.60M | -$31.42M | -$29.59M | -$24.17M |
| Capital expenditure | $1.23M | $3.83M | $3.79M | $5.75M | $5.20M | $3.11M | $1.14M | $25.51M |
| Free cash flow | -$39.88M | -$44.21M | -$45.47M | -$38.27M | -$31.79M | -$34.53M | -$30.73M | -$49.68M |
| Investing cash flow | $45.09M | $12.81M | $34.83M | $28.09M | $29.02M | $18.57M | $28.29M | $15.08M |
| Financing cash flow | $48,000 | $541,000 | $215,000 | $17.63M | $7.96M | -$14,000 | -$12,000 | $123,000 |
| Depreciation & amortization | $1.48M | $1.45M | $1.66M | $1.84M | $1.40M | $1.49M | $1.60M | $1.57M |
| Stock-based compensation | $5.88M | $5.59M | $4.95M | $5.70M | $6.67M | $6.54M | $6.42M | $6.95M |
Free plan shows the latest 8 periods; Pro shows all 22 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.